SILENCE
In patients near end of life, does subcutaneous scopolamine butylbromide compared with placebo, reduce the incidence of death rattle?
Continue reading »Author: David Slessor
RECOVERY REGEN-COV
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial @PeterHorby. medRxiv pre-print 2021 doi: https://doi.org/10.1101/2021.06.15.21258542 Clinical Question In hospitalised patients with COVID-19, does the addition of monoclonal antibodies REGEN-COV (carsirivimab & imdevimab) to standard care, compared with standard care alone, improve 28 day mortality? Background Monoclonal antibodies have been shown to be […]
Continue reading »COVID STEROID 2
In patients with severe COVID, does 12mg dexamethasone vs 6mg dexamethasone increase the number of days alive without life support at 28 days?
Continue reading »McCardle
Treatment of Multisystem Inflammatory Syndrome in Children McArdle. NEJM 2021; 385: 35-45.DOI: 10.1056/NEJMoa2102968 Clinical Question In children with multisystem inflammatory syndrome, what affect do different treatments have on the composite of inotropic support or mechanical ventilation by day 2 or death, and disease severity by day 2? Background Multisystem inflammatory syndrome in children (MIS-C) is a new, rare but serious […]
Continue reading »DEXA-ARDS
In patients with moderate-severe ARDS, does dexamethasone in addition to routine care, compared with routine care alone increase ventilator free days up to day 28?
Continue reading »REMAP-CAP IL-6
In critically ill patients with COVID-19, do the IL-6 receptor antagonists, tocilizumab and sarilumab, compared with standard care, improve respiratory and cardiovascular organ support free days up to day 21?
Continue reading »GRECCO-19
In patients hospitalised with symptomatic coronavirus disease 2019, does the administration of colchicine improve clinical & laboratory outcomes?
Continue reading »PEPTIC
In ICU patients requiring invasive mechanical ventilation, does the use of proton pump inhibitors (PPIs) vs. histamine-2 receptor blockers (H2RBs) for stress-ulcer prophylaxis, reduce 90-day mortality?
Continue reading »ESETT
In patients with status epilepticus who have been treated with benzodiazepines, is Levetriracetam, Valproate or Fosphenyoin more likely to lead to an absence of seizures and improved responsiveness at 60 minutes?
Continue reading »COLCOT
In patients post myocardial infarction, does low dose colchicine compared with placebo, reduce ischaemic cardiovascular events?
Continue reading »